Pursuing a “go-it-alone” strategy through the end of phase II trials, thus postponing the decision of whom, if any, to partner with. The first two alternatives were somewhat consistent with Abgenix’ past business model that yielded revenues in two ways: 1) by issuing exclusive licenses to use XenoMouse for drug development targeting specific diseases to leading pharmaceutical and biotechnology companies and 2) by undertaking the early stages of XenoMouse based drug development and subsequently selling off the rights to further develop and bring the drugs onto the market. In contrast, the “go-it-alone” method would require an expansion of Abgenix’ resource base and capabilities: a more risky approach with the potential of a relatively high value generation. Click here to read more…
- Powered by Article Dashboard manufacturing cost plush toys
- Powered by Article Dashboard fisher price baby toys
- Powered by Article Dashboard licensing plush toys
- abgenix and the xenomouse case solution
- Powered by Article Dashboard vintage fisher price toys
- abgenix and the xenomouse case
- powered by vBulletin baby toys
- Powered by Article Dashboard kid toys for christmas
- powered by phpBB licensing plush toys
- abgenix xenomouse case solution
Related Case Studies:
- Case Study on Issue of Drug Price Control Abstract: This case discusses the issue of the proposed National...
- Case Study on Pfizer Pfizer is the world’s largest pharmaceutical company by sales, having...
- Case Study for Microsoft Dynamics Biota is a leading anti-infective drug development company based in...
- Case Study on Shoppers Drug Mart Corporation Shoppers Drug Mart Corporation (Shoppers) is one of the most...
- Case Study for Cipher Pharmaceuticals Cipher is a specialty pharmaceutical company with a laser focus...